CL2008001577A1 - Metodo para tratar una leucemia positiva en un sujeto resistente a imatinib que comprende el uso de un compuesto derivado de 3-ciano-quinolina. - Google Patents

Metodo para tratar una leucemia positiva en un sujeto resistente a imatinib que comprende el uso de un compuesto derivado de 3-ciano-quinolina.

Info

Publication number: CL2008001577A1
Authority: CL; Chile
Prior art keywords: quinolina; ciano; imatinib; understands; treat
Prior art date: 2007-06-01

Application number

CL200801577A

Other languages

English (en)

Inventor

Becker Hewes

Original Assignee

Wyeth Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-06-01

Filing date

2008-05-30

Publication date

2008-07-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39639071&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008001577(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-05-30 Application filed by Wyeth Corp filed Critical Wyeth Corp

2008-07-25 Publication of CL2008001577A1 publication Critical patent/CL2008001577A1/es

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Quinoline Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

CL200801577A 2007-06-01 2008-05-30 Metodo para tratar una leucemia positiva en un sujeto resistente a imatinib que comprende el uso de un compuesto derivado de 3-ciano-quinolina. CL2008001577A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US93265007P	2007-06-01	2007-06-01

Publications (1)

Publication Number	Publication Date
CL2008001577A1 true CL2008001577A1 (es)	2008-07-25

Family

ID=39639071

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL200801577A CL2008001577A1 (es)	2007-06-01	2008-05-30	Metodo para tratar una leucemia positiva en un sujeto resistente a imatinib que comprende el uso de un compuesto derivado de 3-ciano-quinolina.

Country Status (24)

Country	Link
US (1)	US11103497B2 (es)
EP (4)	EP3002009B1 (es)
JP (3)	JP5888853B2 (es)
KR (1)	KR101493543B1 (es)
CN (1)	CN101686973B (es)
AU (1)	AU2008260070B9 (es)
BR (1)	BRPI0812355A2 (es)
CA (3)	CA2964162C (es)
CL (1)	CL2008001577A1 (es)
CY (2)	CY1115251T1 (es)
DK (2)	DK3002009T3 (es)
ES (2)	ES2881391T3 (es)
HK (1)	HK1142812A1 (es)
HU (1)	HUE055524T2 (es)
IL (1)	IL202407A0 (es)
MX (1)	MX2009013069A (es)
PA (1)	PA8782301A1 (es)
PL (2)	PL2478905T3 (es)
PT (2)	PT3002009T (es)
RU (1)	RU2464026C2 (es)
SI (2)	SI2478905T1 (es)
TW (1)	TW200908982A (es)
WO (1)	WO2008150957A2 (es)
ZA (1)	ZA200908480B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3002009B1 (en)	2007-06-01	2021-07-07	Wyeth LLC	Treatment of imatinib resistant chronic myelogenous leukemia having the mutaton 1457t>c in the bcrabl gene using the compound bosutinib
WO2012122011A2 (en)	2011-03-04	2012-09-13	Glaxosmithkline Llc	Amino-quinolines as kinase inhibitors
TWI547494B (zh)	2011-08-18	2016-09-01	葛蘭素史克智慧財產發展有限公司	作為激酶抑制劑之胺基喹唑啉類
TWI592417B (zh)	2012-09-13	2017-07-21	葛蘭素史克智慧財產發展有限公司	胺基喹唑啉激酶抑制劑之前藥
AR092530A1 (es)	2012-09-13	2015-04-22	Glaxosmithkline Llc	Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
EP2958911B1 (en)	2013-02-21	2017-10-18	GlaxoSmithKline Intellectual Property Development Limited	Quinazolines as kinase inhibitors
KR101733665B1 (ko) *	2015-05-06	2017-05-10	재단법인 지능형 바이오 시스템 설계 및 합성 연구단	진세노사이드 Ｆ1 또는 Ｒｇ3을 유효성분으로 포함하는 글리벡 내성 백혈병 예방 또는 치료용 약학 조성물
AU2020332367A1 (en) *	2019-08-22	2022-02-17	Biohaven Therapeutics Ltd.	Molecules that bind to TDP-43 for the treatment of amyotrophic lateral sclerosis and related disorders
CN115944636A (zh) *	2022-11-01	2023-04-11	华南师范大学	博舒替尼在抑制i-motif结构上的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6002008A (en)	1997-04-03	1999-12-14	American Cyanamid Company	Substituted 3-cyano quinolines
US6297258B1 (en)	1998-09-29	2001-10-02	American Cyanamid Company	Substituted 3-cyanoquinolines
CA2434526C (en) *	2001-01-25	2011-11-01	Bristol Myers Squibb Company	Methods of administering epothilone analogs for the treatment of cancer
EP2341133A1 (en)	2001-10-05	2011-07-06	Novartis AG	Mutated Abl kinase domains
TWI275390B (en) *	2002-04-30	2007-03-11	Wyeth Corp	Process for the preparation of 7-substituted-3- quinolinecarbonitriles
US20050010780A1 (en) *	2003-07-09	2005-01-13	Kane John Richard	Method and apparatus for providing access to personal information
US7417148B2 (en) *	2003-11-06	2008-08-26	Wyeth	4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML)
KR20080011403A (ko)	2005-04-25	2008-02-04	화이자 인크.	미오스타틴에 대한 항체
PL1896470T3 (pl) *	2005-05-16	2011-03-31	Irm Llc	Pochodne pirolopirydynowe jako inhibitory kinazy białkowej
EP1904654A2 (en)	2005-07-15	2008-04-02	Brystol-Myers Squibb Company	Methods of identifying and treating individuals exhibiting mutant src kinase polypeptides
ES2533464T3 (es)	2005-10-06	2015-04-10	Eli Lilly And Company	Anticuerpos anti-miostatina
EP1948820A2 (en)	2005-11-04	2008-07-30	Bristol-Myers Squibb Pharma Company	T315a and f317i mutations of bcr-abl kinase domain
EP3002009B1 (en) *	2007-06-01	2021-07-07	Wyeth LLC	Treatment of imatinib resistant chronic myelogenous leukemia having the mutaton 1457t>c in the bcrabl gene using the compound bosutinib

2008
- 2008-05-30 EP EP15191756.4A patent/EP3002009B1/en active Active
- 2008-05-30 TW TW097120369A patent/TW200908982A/zh unknown
- 2008-05-30 CL CL200801577A patent/CL2008001577A1/es unknown
- 2008-05-30 EP EP08769857A patent/EP2152267A2/en not_active Withdrawn
- 2008-05-30 PT PT151917564T patent/PT3002009T/pt unknown
- 2008-05-30 EP EP12160638.8A patent/EP2478905B1/en active Active
- 2008-05-30 EP EP14167958.9A patent/EP2777704A3/en not_active Withdrawn
- 2008-05-30 PL PL12160638T patent/PL2478905T3/pl unknown
- 2008-05-30 KR KR1020097027540A patent/KR101493543B1/ko active IP Right Grant
- 2008-05-30 CA CA2964162A patent/CA2964162C/en active Active
- 2008-05-30 JP JP2010510505A patent/JP5888853B2/ja active Active
- 2008-05-30 ES ES15191756T patent/ES2881391T3/es active Active
- 2008-05-30 DK DK15191756.4T patent/DK3002009T3/da active
- 2008-05-30 CN CN2008800219346A patent/CN101686973B/zh active Active
- 2008-05-30 PT PT121606388T patent/PT2478905E/pt unknown
- 2008-05-30 AU AU2008260070A patent/AU2008260070B9/en active Active
- 2008-05-30 DK DK12160638.8T patent/DK2478905T3/da active
- 2008-05-30 CA CA2688467A patent/CA2688467C/en active Active
- 2008-05-30 RU RU2009144128/15A patent/RU2464026C2/ru active
- 2008-05-30 PA PA20088782301A patent/PA8782301A1/es unknown
- 2008-05-30 MX MX2009013069A patent/MX2009013069A/es active IP Right Grant
- 2008-05-30 US US12/129,935 patent/US11103497B2/en active Active
- 2008-05-30 PL PL15191756T patent/PL3002009T3/pl unknown
- 2008-05-30 BR BRPI0812355-1A2A patent/BRPI0812355A2/pt not_active Application Discontinuation
- 2008-05-30 HU HUE15191756A patent/HUE055524T2/hu unknown
- 2008-05-30 WO PCT/US2008/065215 patent/WO2008150957A2/en active Application Filing
- 2008-05-30 ES ES12160638.8T patent/ES2477567T3/es active Active
- 2008-05-30 SI SI200831212T patent/SI2478905T1/sl unknown
- 2008-05-30 CA CA2868899A patent/CA2868899C/en active Active
- 2008-05-30 SI SI200832178T patent/SI3002009T1/sl unknown
2009
- 2009-11-29 IL IL202407A patent/IL202407A0/en unknown
- 2009-11-30 ZA ZA200908480A patent/ZA200908480B/xx unknown
2010
- 2010-09-28 HK HK10109282.6A patent/HK1142812A1/xx unknown
2014
- 2014-01-31 JP JP2014016309A patent/JP2014111629A/ja active Pending
- 2014-06-03 CY CY20141100395T patent/CY1115251T1/el unknown
2015
- 2015-11-24 JP JP2015229117A patent/JP2016074700A/ja active Pending
2021
- 2021-08-03 CY CY20211100693T patent/CY1124391T1/el unknown

Also Published As

Publication number	Publication date
SI3002009T1 (sl)	2021-09-30
CA2688467A1 (en)	2008-12-11
AU2008260070A1 (en)	2008-12-11
DK2478905T3 (da)	2014-06-30
RU2009144128A (ru)	2011-07-20
PL2478905T3 (pl)	2014-10-31
EP2478905A2 (en)	2012-07-25
PA8782301A1 (es)	2009-01-23
EP2152267A2 (en)	2010-02-17
CN101686973A (zh)	2010-03-31
EP3002009B1 (en)	2021-07-07
CN101686973B (zh)	2013-06-19
RU2464026C2 (ru)	2012-10-20
WO2008150957A2 (en)	2008-12-11
US20080318971A1 (en)	2008-12-25
MX2009013069A (es)	2010-03-17
KR101493543B1 (ko)	2015-02-13
EP2478905B1 (en)	2014-05-14
IL202407A0 (en)	2010-06-30
JP2016074700A (ja)	2016-05-12
CA2964162A1 (en)	2008-12-11
HK1142812A1 (en)	2010-12-17
ZA200908480B (en)	2010-08-25
HUE055524T2 (hu)	2021-11-29
EP2777704A2 (en)	2014-09-17
WO2008150957A3 (en)	2009-08-06
CY1115251T1 (el)	2017-01-04
PT3002009T (pt)	2021-08-02
AU2008260070B9 (en)	2012-01-19
ES2477567T3 (es)	2014-07-17
DK3002009T3 (da)	2021-08-02
ES2881391T3 (es)	2021-11-29
CY1124391T1 (el)	2022-07-22
AU2008260070B2 (en)	2011-08-18
EP3002009A2 (en)	2016-04-06
BRPI0812355A2 (pt)	2015-01-27
SI2478905T1 (sl)	2014-07-31
KR20100017983A (ko)	2010-02-16
JP2010529038A (ja)	2010-08-26
TW200908982A (en)	2009-03-01
PT2478905E (pt)	2014-07-16
CA2868899A1 (en)	2008-12-11
JP2014111629A (ja)	2014-06-19
PL3002009T3 (pl)	2021-12-13
CA2688467C (en)	2015-05-12
CA2868899C (en)	2017-06-13
EP2777704A3 (en)	2015-01-21
EP2478905A3 (en)	2013-01-16
JP5888853B2 (ja)	2016-03-22
CA2964162C (en)	2019-12-31
US11103497B2 (en)	2021-08-31
EP3002009A3 (en)	2016-07-06

Publication	Publication Date	Title
CL2008001577A1 (es)	2008-07-25	Metodo para tratar una leucemia positiva en un sujeto resistente a imatinib que comprende el uso de un compuesto derivado de 3-ciano-quinolina.
BRPI0811189A2 (pt)	2014-10-29	Ferramenta de nivelação composta.
BRPI0923786A2 (pt)	2016-07-26	compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos
BRPI0817475A2 (pt)	2017-05-16	meio legível por computador.
BRPI0815717A2 (pt)	2015-02-10	Compostos de imidazopirazina.
BRPI0816970A2 (pt)	2015-03-24	1,3-dissubstituídas-4-fenil-1h-piridin-2-onas
BRPI0918472A2 (pt)	2015-12-01	composto 2,4-diaminopirimidina
CR10353A (es)	2009-01-09	Nuevos compuestos.
ATE473309T1 (de)	2010-07-15	Werkzeug mit beschichtung
DE602008000866D1 (de)	2010-05-06	Verbunddrehbank
DE602008003113D1 (de)	2010-12-02	Türschloss
BRPI0912716A2 (pt)	2015-10-13	composto.
DE502008000004D1 (de)	2009-05-07	Explosionshemmendes Bauelement
BRPI0818422A2 (pt)	2015-04-22	Processo para a preparação de melamina.
BRPI0916395A2 (pt)	2016-02-16	compostos de 1,6-di-hidro-2h-3-oxa-6-aza-as-indaceno
FI20075822A0 (fi)	2007-11-20	Ovenlukko
BRPI0815716A2 (pt)	2015-02-10	Decapagem secundária econômica.
FR2936217B1 (fr)	2010-10-22	Barge semi submersible modulaire.
NO20085258L (no)	2010-06-17	Stigerorsventil
BRPI0812460A2 (pt)	2014-12-02	" compostos orgânicos ".
DE102007020399A8 (de)	2009-03-19	Tank, insbesondere Erdtank
DE502008002040D1 (de)	2011-02-03	Fahrzeughilfsrahmen
NL1033185A1 (nl)	2008-03-17	Tank.
BRPI0818848A2 (pt)	2015-04-14	Compostos de 2,3-di-idro-benzofurano
FI20075944A0 (fi)	2007-12-20	Pinnoitusmenetelmä